Proteostatis stock plunges on cystic fibrosis triple combo data
March 25, 2019 at 12:35 PM EDT
What would otherwise be promising data led to a 60 percent stock price slide, as it falls far below both triple combination treatments being developed by the cystic fibrosis market leader, Vertex.
